TSHA outlines pivotal trial milestones, including process performance qualification completion by Q4 2026 and interim analysis in H1 2027.
Taysha Gene Therapies aims to complete process performance qualification (PPQ) for its REVEAL trial by Q4 2026, according to management commentary. The company also plans a six-month interim analysis and expects FDA feedback in the first half of 2027, reflecting progress in its gene therapy pipeline.
In Q2 2026, Taysha completed dosing for both the REVEAL pivotal trial and the ASPIRE trial, marking a key operational milestone. The company did not provide prior-period comparisons but emphasized forward-looking targets for regulatory and clinical advancement.
No immediate market reaction was detailed in the source, though the timeline updates may influence investor sentiment around TSHA’s regulatory and commercialization strategy.